Questions to Ask a Clinician About Compounded Tirzepatide Shelf Life
The only real answer comes from the pharmacy that made the vial, because the beyond-use date it assigned is specific to that formulation and that batch. No general number covers compounded tirzepatide. So the useful questions are not variations on how long it keeps. They are questions that establish who set the date and what it was based on.
Reviewed by Dr. Michael Aziz, MD, Internal Medicine
Why the question has to be redirected
An approved product’s expiration date rests on stability data generated by the manufacturer for that exact formulation and reviewed by FDA before marketing. Compounded preparations have no equivalent dossier. FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed, and dating falls to the compounding pharmacy under the standards covering the preparation it made.
That is why a clinician who answers a shelf life question with a confident general number should prompt a follow-up rather than reassurance. The credible response names a pharmacy and points at a label.
Before those questions even get asked, it is worth seeing which providers answer them in public. Some keep the details behind a sign-up, others post them openly. Ro and Hims & Hers describe their pharmacy networks in broad strokes, LillyDirect sells the approved drug straight to eligible patients, and an operator such as HealthRX keeps published guidance on compounded tirzepatide that a prospective patient can read without an account. A clinic that documents dating and sourcing openly is usually the one that will answer the harder questions at the visit.
The questions worth asking
Which pharmacy compounded this, and can I have its name and license details? Everything else depends on this. FDA has pointed out that people buying compounded drugs online may not know the identity of the compounder at all, and the agency has documented fraudulent products where the pharmacy named on the label either did not exist or did not make the product.
Is this a 503A pharmacy or a registered outsourcing facility? The two operate under different parts of federal law. Outsourcing facilities registered under section 503B follow current good manufacturing practice and are inspected by FDA on a risk-based schedule. Neither makes a compounded drug FDA-approved, but the oversight differs.
What concentration is being dispensed, and has it changed since the last fill? Compounded strengths vary between pharmacies. Research comparing follow-on GLP-1 polypeptide preparations found that process and compounding choices affect the properties and quality of the finished product, so a change in source is a substantive change.
Does this preparation arrive ready to use, or does it need reconstitution? Those behave differently and are dated differently. Work on lyophilized peptide formulations has documented particulate formation and stability changes tied to reconstitution, which is one reason a powder and a solution cannot share a shelf life assumption.
Is the vial preserved and intended for repeated entry, or single use? Preservative status is a formulation decision made by the pharmacy, and it determines whether repeated puncture is contemplated at all. It is not something to infer from how much liquid is in the vial.
What should happen if a shipment arrives warm? FDA says injectable GLP-1 drugs require refrigeration as indicated in their package inserts, reports complaints about compounded GLP-1 products arriving warm or with inadequate ice packs, and advises against using product in that condition. A provider should have a replacement process, not a judgment call.
Who do I call after hours, and how fast do they answer? A telehealth red flag identified by FDA is a company with no licensed doctor available to answer questions once medicine has been delivered.
| Question | What a solid answer contains | What a weak answer sounds like |
|---|---|---|
| Which pharmacy made it | A named, state-licensed pharmacy or registered outsourcing facility | “Our partner pharmacy network” |
| Who sets the date | The pharmacy, based on its formulation and testing | A general figure quoted for all compounded products |
| Concentration dispensed | A specific strength, confirmed against the label | “Same as the brand” |
| Ready to use or reconstituted | Stated plainly, with the label matching | Uncertainty about which was shipped |
| Warm shipment policy | Do not use, contact us, replacement sent | “Use your judgment if it still feels cool” |
| Post-delivery contact | A named clinician or pharmacist reachable directly | Chat form with no stated response time |
Questions about supply and legality that belong in the same conversation
Federal compounding law limits when a compounded version of a commercially available drug is appropriate, and FDA has issued final guidance addressing compounded products that are essentially copies under both section 503A and section 503B. Compounders may also prepare versions of a drug on FDA’s shortage list when conditions in federal law are met. Asking a prescriber why a compounded preparation is being used for a given patient, rather than an approved product, is a fair question with a real answer.
Sourcing is worth raising too. FDA has urged compounders to know their bulk substance and excipient suppliers, and has established an import alert covering GLP-1 active ingredients with potential quality concerns. Market surveillance research on semaglutide products sold online without a prescription found quality and seller conduct problems that no dating question can fix.
Where cost enters the conversation
Most people asking about shelf life are really asking whether they can afford to replace something. Putting the price question directly to the provider is more productive than working backward from a date. Eden, Ivim Health and FormBlends publish cash pricing for physician-supervised access, Calibrate builds its program around insurance navigation, and LillyDirect sells the approved product directly for eligible patients. Comparing those on total cost per month, with the pharmacy named in each case, answers the underlying question better than any general dating rule could.
What not to ask for
A clinician should not be expected to supply a rule of thumb for keeping product past its date, and a good one will decline. FDA has stated that poor compounding practices can result in contamination or incorrect amounts of active ingredient, both of which can cause serious injury. The date exists because that risk is not visible from the outside, so a workaround delivered verbally is worth less than the label it contradicts.
Frequently asked questions
Is it reasonable to ask for the beyond-use date before ordering?
Yes, though the honest reply may be that dating is assigned per batch and appears on the dispensed label. What a provider can say in advance is which pharmacy compounds its prescriptions and how dating is communicated, which is enough to judge whether the process is transparent.
What if the prescriber does not know which pharmacy filled the order?
That is informative in itself. Analysis written for clinicians handling compounded GLP-1 prescriptions notes that prescribers often lack formulation details for what their patients received. A provider that cannot trace its own supply cannot answer questions about dating, quality, or a recall.
Does asking about preservatives change anything practical?
It clarifies what the vial was designed for. Preservative status is a formulation decision that determines whether repeated entry is contemplated, and it is set by the pharmacy rather than chosen by the patient. Guessing from vial size is how contamination risk gets introduced.
Should the same questions be asked at every refill?
The pharmacy identity and concentration questions are worth repeating, because sources can change without notice and manufacturing differences affect finished quality. The rest can be settled once, provided the answers are documented somewhere the patient can find them later.
What if a provider says its compounded product is the same as the approved drug?
FDA lists that specific claim as a telehealth warning sign. Compounded drugs are not FDA-approved, are not generics, and have not been reviewed for safety, effectiveness or quality before marketing. A provider making that claim is describing its marketing rather than the regulatory position.
